{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:24:02Z","timestamp":1787671442477,"version":"build-2736575974"},"reference-count":95,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:00:00Z","timestamp":1696982400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cardiotoxicity is a well-known adverse effect of cancer-related therapy that has a significant influence on patient outcomes and quality of life. The use of antineoplastic drugs to treat colorectal cancers (CRCs) is associated with a number of undesirable side effects including cardiac complications. For both sexes, CRC ranks second and accounts for four out of every ten cancer deaths. According to the reports, almost 39% of patients with colorectal cancer who underwent first-line chemotherapy suffered cardiovascular impairment. Although 5-fluorouracil is still the backbone of chemotherapy regimen for colorectal, gastric, and breast cancers, cardiotoxicity caused by 5-fluorouracil might affect anywhere from 1.5% to 18% of patients. The precise mechanisms underlying cardiotoxicity associated with CRC treatment are complex and may involve the modulation of various signaling pathways crucial for maintaining cardiac health including TKI ErbB2 or NRG-1, VEGF, PDGF, BRAF\/Ras\/Raf\/MEK\/ERK, and the PI3\/ERK\/AMPK\/mTOR pathway, resulting in oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis, ultimately damaging cardiac tissue. Thus, the identification and management of cardiotoxicity associated with CRC drug therapy while minimizing the negative impact have become increasingly important. The purpose of this review is to catalog the potential cardiotoxicities caused by anticancer drugs and targeted therapy used to treat colorectal cancer as well as strategies focused on early diagnosing, prevention, and treatment of cardiotoxicity associated with anticancer drugs used in CRC therapy.<\/jats:p>","DOI":"10.3390\/ph16101441","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T08:07:12Z","timestamp":1697011632000},"page":"1441","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Recent Perspectives on Cardiovascular Toxicity Associated with Colorectal Cancer Drug Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Monu Kumar","family":"Kashyap","sequence":"first","affiliation":[{"name":"Goel Institute of Pharmaceutical Sciences, Faizabad Road, Lucknow 226028, Uttar Pradesh, India"},{"name":"Dr. A. P. J. Abdul Kalam Technical University, Lucknow 222001, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubhada V.","family":"Mangrulkar","sequence":"additional","affiliation":[{"name":"Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur 441002, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8825-3034","authenticated-orcid":false,"given":"Sapana","family":"Kushwaha","sequence":"additional","affiliation":[{"name":"National Institute of Pharmaceutical Education and Research, Raebareli 229010, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8487-3885","authenticated-orcid":false,"given":"Akash","family":"Ved","sequence":"additional","affiliation":[{"name":"Dr. A. P. J. Abdul Kalam Technical University, Lucknow 222001, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5881-7927","authenticated-orcid":false,"given":"Mayur B.","family":"Kale","sequence":"additional","affiliation":[{"name":"Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur 441002, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitu L.","family":"Wankhede","sequence":"additional","affiliation":[{"name":"Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur 441002, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh G.","family":"Taksande","sequence":"additional","affiliation":[{"name":"Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur 441002, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman B.","family":"Upaganlawar","sequence":"additional","affiliation":[{"name":"SNJB\u2019s Shriman Sureshdada Jain Collge of Pharmacy, Neminagar, Chandwad, Nadik 423101, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milind J.","family":"Umekar","sequence":"additional","affiliation":[{"name":"Smt. Kishoritai Bhoyar College of Pharmacy, New Kamptee, Nagpur 441002, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8597-7763","authenticated-orcid":false,"given":"Sushruta","family":"Koppula","sequence":"additional","affiliation":[{"name":"College of Biomedical and Health Sciences, Konkuk University, Chungju-Si 27478, Chungcheongbuk Do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3379-4797","authenticated-orcid":false,"given":"Spandana Rajendra","family":"Kopalli","sequence":"additional","affiliation":[{"name":"Department of Bioscience and Biotechnology, Sejong University, Gwangjin-gu, Seoul 05006, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"180","DOI":"10.5694\/j.1326-5377.2011.tb03766.x","article-title":"Costs and Cost-effectiveness of Full Implementation of a Biennial Faecal Occult Blood Test Screening Program for Bowel Cancer in Australia","volume":"194","author":"Pignone","year":"2011","journal-title":"Med. J. Aust."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e018403","DOI":"10.1161\/JAHA.120.018403","article-title":"Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines","volume":"9","author":"Alexandre","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Bohdan, M., Kowalczys, A., Mickiewicz, A., Grucha\u0142a, M., and Lewicka, E. (2021). Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. J. Clin. Med., 10.","DOI":"10.3390\/jcm10081647"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of Anticancer Treatments: Epidemiology, Detection, and Management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","first-page":"39","article-title":"Cardiotoxicity in Cancer Patients Treated with Chemotherapy: A Systematic Review","volume":"16","author":"Lima","year":"2022","journal-title":"Int. J. Health Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1042\/CS20200305","article-title":"Cardiotoxic Effects of Angiogenesis Inhibitors","volume":"135","author":"Dobbin","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"A190","DOI":"10.1016\/j.jval.2015.03.1102","article-title":"Risk of Cardiotoxicity and All-Cause Mortality in Breast Cancer Patients after Adjuvant Chemotherapy or Hormonal Therapy","volume":"18","author":"Wittayanukorn","year":"2015","journal-title":"Value Health"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaccao.2022.08.010","article-title":"Longitudinal Right Ventricular Systolic Function Changes in Breast Cancer Patients Treated with Cardiotoxic Cancer Therapy","volume":"4","author":"Demissei","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ansari, A., Hussain, A., Wadekar, R., Altamimi, M.A., Malik, A., Mujtaba, M.A., Ansari, M.Y., Siddique, M.U.M., and Goyal, S.N. (2023). Nanovesicles Based Drug Targeting to Control Tumor Growth and Metastasis. Adv. Cancer Biol.-Metastasis, 7.","DOI":"10.1016\/j.adcanc.2022.100083"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"102282","DOI":"10.1016\/j.ctrv.2021.102282","article-title":"Pathophysiology, Diagnosis and Management of Cardiac Toxicity Induced by Immune Checkpoint Inhibitors and BRAF and MEK Inhibitors","volume":"100","author":"Arangalage","year":"2021","journal-title":"Cancer Treat. Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pharmthera.2018.06.017","article-title":"Cardiotoxicity Mechanisms of the Combination of BRAF-Inhibitors and MEK-Inhibitors","volume":"192","author":"Bronte","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cai, T., Jiang, J., Yao, W., Hu, Y., Kong, S., Fan, Q., Yan, X., Li, F., and Shi, Z. (2023). Pirfenidone Inhibits Stromal Collagen Deposition and Improves Intra-Tumoral Delivery and Antitumor Efficacy of Pegylated Liposomal Doxorubicin. Biomed. Pharmacother., 157.","DOI":"10.1016\/j.biopha.2022.114015"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jaccao.2022.07.014","article-title":"Cardiotoxicity of T-Cell Antineoplastic Therapies","volume":"4","author":"Ganatra","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic Colorectal Cancer: ESMO Clinical Practice Guideline for Diagnosis, Treatment and Follow-Up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jaccao.2022.04.007","article-title":"Late-Onset Immunotherapy-Induced Myocarditis 2 Years after Checkpoint Inhibitor Initiation","volume":"4","author":"Nguyen","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bioactmat.2022.10.004","article-title":"Sustained Co-Delivery of 5-Fluorouracil and Cis-Platinum via Biodegradable Thermo-Sensitive Hydrogel for Intraoperative Synergistic Combination Chemotherapy of Gastric Cancer","volume":"23","author":"Chen","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/CIRCRESAHA.109.206920","article-title":"Molecular Mechanisms of Cardiovascular Toxicity of Targeted Cancer Therapeutics","volume":"106","author":"Cheng","year":"2010","journal-title":"Circ. Res."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Choksey, A., and Timm, K.N. (2021). Cancer Therapy-Induced Cardiotoxicity\u2014A Metabolic Perspective on Pathogenesis, Diagnosis and Therapy. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010441"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100745","DOI":"10.1016\/j.esmoop.2022.100745","article-title":"Targeting KRASG12C in Colorectal Cancer: The Beginning of a New Era","volume":"8","author":"Ciardiello","year":"2023","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jcecho.2011.05.007","article-title":"Cardiotoxicity of Novel Molecular Targeted Therapies of Cancer","volume":"21","author":"Venturini","year":"2011","journal-title":"J. Cardiovasc. Echogr."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"110492","DOI":"10.1016\/j.cellsig.2022.110492","article-title":"Cellular and Molecular Basis of Therapeutic Approaches to Breast Cancer","volume":"101","author":"Shakya","year":"2023","journal-title":"Cell Signal"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/157340311799960645","article-title":"Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment","volume":"7","author":"Volkova","year":"2012","journal-title":"Curr. Cardiol. Rev."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.1038\/srep44735","article-title":"Doxorubicin Induces Cardiotoxicity through Upregulation of Death Receptors Mediated Apoptosis in Cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated Cell Death Pathways in Doxorubicin-Induced Cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2022.01.096","article-title":"Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors","volume":"4","author":"Glen","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Grela-Wojewoda, A., Pacholczak-Madej, R., Adamczyk, A., Korman, M., and P\u00fcsk\u00fcll\u00fco\u011flu, M. (2022). Cardiotoxicity Induced by Protein Kinase Inhibitors in Patients with Cancer. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052815"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jare.2021.11.008","article-title":"Polymeric Nanocarriers: A Promising Tool for Early Diagnosis and Efficient Treatment of Colorectal Cancer","volume":"39","author":"Haider","year":"2022","journal-title":"J. Adv. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41698-017-0034-x","article-title":"Precision Cardio-Oncology: Understanding the Cardiotoxicity of Cancer Therapy","volume":"1","author":"Han","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1161\/01.CIR.0000138190.50127.6A","article-title":"Raf-1 Kinase Is Required for Cardiac Hypertrophy and Cardiomyocyte Survival in Response to Pressure Overload","volume":"110","author":"Harris","year":"2004","journal-title":"Circulation"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/OTT.S149716","article-title":"Assessment of the Cardiac Safety between Cetuximab and Panitumumab as Single Therapy in Chinese Chemotherapy-Refractory MCRC","volume":"11","author":"Tang","year":"2017","journal-title":"OncoTargets Ther."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Degirmenci, U., Wang, M., and Hu, J. (2020). Targeting Aberrant RAS\/RAF\/MEK\/ERK Signaling for Cancer Therapy. Cells, 9.","DOI":"10.3390\/cells9010198"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00280-015-2827-3","article-title":"A Phase I Open-Label Trial Evaluating the Cardiovascular Safety of Regorafenib in Patients with Advanced Cancer","volume":"76","author":"Jones","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.rpor.2020.02.005","article-title":"Cardiotoxicity of Radiation Therapy in Esophageal Cancer","volume":"25","author":"Hodek","year":"2020","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e12705","DOI":"10.1097\/MD.0000000000012705","article-title":"Risk of Regorafenib-Induced Cardiovascular Events in Patients with Solid Tumors","volume":"97","author":"Chen","year":"2018","journal-title":"Medicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.01.001","article-title":"The Complex Network of Transcription Factors, Immune Checkpoint Inhibitors and Stemness Features in Colorectal Cancer: A Recent Update","volume":"89","author":"Merhi","year":"2023","journal-title":"Semin. Cancer Biol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Jacobs, A.T., Martinez Castaneda-Cruz, D., Rose, M.M., and Connelly, L. (2022). Targeted Therapy for Breast Cancer: An Overview of Drug Classes and Outcomes. Biochem. Pharmacol., 204.","DOI":"10.1016\/j.bcp.2022.115209"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"721107","DOI":"10.3389\/fcvm.2021.721107","article-title":"Estimating Risk of Cardiovascular Disease among Long-Term Colorectal Cancer Survivors: A Nationwide Cohort Study","volume":"8","author":"Jeong","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Jiao, Y., Li, Y., Zhang, J., Zhang, S., Zha, Y., and Wang, J. (2022). RRM2 Alleviates Doxorubicin-Induced Cardiotoxicity through the AKT\/MTOR Signaling Pathway. Biomolecules, 12.","DOI":"10.3390\/biom12020299"},{"key":"ref_40","first-page":"27","article-title":"Molecular and Cellular Mechanisms of Cardiotoxicity","volume":"109","author":"Kang","year":"2001","journal-title":"Environ. Health Perspect."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"797","DOI":"10.21037\/jgo.2019.03.04","article-title":"Cardiovascular Complications of Metastatic Colorectal Cancer Treatment","volume":"10","author":"Keramida","year":"2019","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_42","first-page":"395","article-title":"Cardiotoxicity Associated with Cancer Therapy: Pathophysiology and Prevention","volume":"32","year":"2013","journal-title":"Rev. Port. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jaccao.2022.07.012","article-title":"Fulminant Cardiotoxicity in a Patient with Cardiac Lymphoma Treated with CAR-T Cells","volume":"4","author":"Koch","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/VHRM.S108874","article-title":"Cardiovascular Toxicities of BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Preventive Strategies and Cardiovascular Surveillance","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Kourek, C., Touloupaki, M., Rempakos, A., Loritis, K., Tsougkos, E., Paraskevaidis, I., and Briasoulis, A. (2022). Cardioprotective Strategies from Cardiotoxicity in Cancer Patients: A Comprehensive Review. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9080259"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic Microangiopathy as a Cause of Cardiovascular Toxicity from the BCR-ABL1 Tyrosine Kinase Inhibitor Ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2017.02.009","article-title":"Incidence of Capecitabine-Related Cardiotoxicity in Different Treatment Schedules of Metastatic Colorectal Cancer: A Retrospective Analysis of the CAIRO Studies of the Dutch Colorectal Cancer Group","volume":"76","author":"Kwakman","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Liu, C., Wu, K., Li, J., Mu, X., Gao, H., and Xu, X. (2023). Nanoparticle-Mediated Therapeutic Management in Cholangiocarcinoma Drug Targeting: Current Progress and Future Prospects. Biomed. Pharmacother., 158.","DOI":"10.1016\/j.biopha.2022.114135"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, Prevalence, and Outcomes of Anticancer Therapy-Induced Cardiotoxicity: The CARDIOTOX Registry","volume":"41","author":"Lyon","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_50","first-page":"1","article-title":"The Role of PDGFs and PDGFRs in Colorectal Cancer","volume":"2017","author":"Balacescu","year":"2017","journal-title":"Mediat. Inflamm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"102332","DOI":"10.1016\/j.coph.2022.102332","article-title":"Update on Anti-Fibrotic Pharmacotherapies in Skeletal Muscle Disease","volume":"68","author":"Muraine","year":"2023","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.phoj.2022.06.004","article-title":"Incidence and Risk Factors of Anthracycline-Induced Cardiotoxicity in Long-Term Survivors of Pediatric Cancer: A Population Based Cohort Study","volume":"7","author":"Nathan","year":"2022","journal-title":"Pediatr. Hematol. Oncol. J."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy","volume":"16","author":"Negishi","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1111\/j.1440-1746.2012.07200.x","article-title":"Molecular Pathways in Colorectal Cancer","volume":"27","author":"Biankin","year":"2012","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"100147","DOI":"10.1016\/j.medidd.2022.100147","article-title":"A Review of the Pharmacodynamic Effect of Chemo-Herbal Drug Combinations Therapy for Cancer Treatment","volume":"17","author":"Okem","year":"2023","journal-title":"Med. Drug Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.toxrep.2022.09.001","article-title":"Molecular Mechanisms Associated with the Chemoprotective Role of Protocatechuic Acid and Its Potential Benefits in the Amelioration of Doxorubicin-Induced Cardiotoxicity: A Review","volume":"9","author":"Okpara","year":"2022","journal-title":"Toxicol. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100427","DOI":"10.1016\/j.esmoop.2022.100427","article-title":"Continuation of Fluoropyrimidine Treatment with S-1 after Cardiotoxicity on Capecitabine- or 5-Fluorouracil-Based Therapy in Patients with Solid Tumours: A Multicentre Retrospective Observational Cohort Study","volume":"7","author":"Osterlund","year":"2022","journal-title":"ESMO Open"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.critrevonc.2014.12.006","article-title":"The Role of the PI3K Pathway in Colorectal Cancer","volume":"94","author":"Rabbie","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"100642","DOI":"10.1016\/j.esmoop.2022.100642","article-title":"FOxTROT2: Innovative Trial Design to Evaluate the Role of Neoadjuvant Chemotherapy for Treating Locally Advanced Colon Cancer in Older Adults or Those with Frailty","volume":"8","author":"Platt","year":"2023","journal-title":"ESMO Open"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.cell.2009.04.060","article-title":"Neuregulin1\/ErbB4 Signaling Induces Cardiomyocyte Proliferation and Repair of Heart Injury","volume":"138","author":"Bersell","year":"2009","journal-title":"Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1053\/j.semnuclmed.2022.02.001","article-title":"Nuclear Medicine Imaging Methods of Radiation-Induced Cardiotoxicity","volume":"52","author":"Polomski","year":"2022","journal-title":"Semin. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive Cardiotoxicity","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4103\/jpcs.jpcs_33_17","article-title":"Cancer Therapy-Induced Cardiotoxicity: Review and Algorithmic Approach toward Evaluation","volume":"3","author":"Purkayastha","year":"2017","journal-title":"J. Pract. Cardiovasc. Sci."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.gastro.2015.03.016","article-title":"VEGFR2 Signaling Prevents Colorectal Cancer Cell Senescence to Promote Tumorigenesis in Mice with Colitis","volume":"149","author":"Foersch","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ajps.2022.09.002","article-title":"Ferroptosis-Based Nano Delivery Systems Targeted Therapy for Colorectal Cancer: Insights and Future Perspectives","volume":"17","author":"Qiao","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"155250","DOI":"10.1016\/j.metabol.2022.155250","article-title":"Insights on the Molecular Targets of Cardiotoxicity Induced by Anticancer Drugs: A Systematic Review Based on Proteomic Findings","volume":"134","author":"Carvalho","year":"2022","journal-title":"Metabolism"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaccao.2022.11.006","article-title":"Cancer Immunotherapy beyond Checkpoint Blockade","volume":"4","author":"Welty","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jaccao.2022.01.101","article-title":"The Role of Cardioprotection in Cancer Therapy Cardiotoxicity","volume":"4","author":"Omland","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"10197","DOI":"10.2147\/OTT.S264156","article-title":"Alternative Treatment Options in Patients with Colorectal Cancer Who Encounter Fluoropyrimidine-Induced Cardiotoxicity","volume":"13","author":"Saif","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1158\/1535-7163.MCT-11-0312","article-title":"Targeting FGFR\/PDGFR\/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes in Pancreatic Cancer","volume":"10","author":"Taeger","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 Tyrosine Kinase Inhibitors: Emphasis on Ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int. J. Cardiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101380","DOI":"10.1016\/j.cpcardiol.2022.101380","article-title":"Cardiovascular Outcomes and Hospitalizations in Asian Patients Receiving Immune Checkpoint Inhibitors: A Population-Based Study","volume":"48","author":"Chan","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.gendis.2022.05.006","article-title":"Targeting RAS-RAF-MEK-ERK Signaling Pathway in Human Cancer: Current Status in Clinical Trials","volume":"10","author":"Song","year":"2023","journal-title":"Genes Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2007.11.005","article-title":"Potential Predictive Markers of Response to EGFR-Targeted Therapies in Colorectal Cancer","volume":"66","author":"Spano","year":"2008","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3892\/ol.2017.5557","article-title":"Targeting the Ras\/Raf\/MEK\/ERK Pathway in Hepatocellular Carcinoma","volume":"13","author":"Yang","year":"2017","journal-title":"Oncol. Lett."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.bioactmat.2022.12.027","article-title":"Functionalized Liposomes for Targeted Breast Cancer Drug Delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact. Mater."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/med.21463","article-title":"Breakthroughs in Modern Cancer Therapy and Elusive Cardiotoxicity: Critical Research-Practice Gaps, Challenges, and Insights","volume":"38","author":"Zheng","year":"2018","journal-title":"Med. Res. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.3748\/wjg.v20.i15.4178","article-title":"Targeting MTOR Network in Colorectal Cancer Therapy","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s10557-020-06941-x","article-title":"The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity","volume":"34","author":"Timm","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jaccao.2022.06.002","article-title":"How to Manage and Monitor Cardiac Dysfunction in Patients with Metastatic HER2-Positive Breast Cancer","volume":"4","author":"Dent","year":"2022","journal-title":"JACC CardioOncol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Trapani, D., Zagami, P., Nicol\u00f2, E., Pravettoni, G., and Curigliano, G. (2020). Management of Cardiac Toxicity Induced by Chemotherapy. J. Clin. Med., 9.","DOI":"10.3390\/jcm9092885"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"863314","DOI":"10.3389\/fcvm.2022.863314","article-title":"Novel Therapeutics for Anthracycline Induced Cardiotoxicity","volume":"9","author":"Vuong","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Kubin, T., Cetinkaya, A., Kubin, N., Bramlage, P., Sen-Hild, B., Gajawada, P., Akint\u00fcrk, H., Sch\u00f6nburg, M., Schaper, W., and Choi, Y.-H. (2020). The MEK\/ERK Module Is Reprogrammed in Remodeling Adult Cardiomyocytes. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176348"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.radonc.2022.04.030","article-title":"Murine Models of Radiation Cardiotoxicity: A Systematic Review and Recommendations for Future Studies","volume":"173","author":"Walls","year":"2022","journal-title":"Radiother. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.trecan.2015.07.004","article-title":"The Emerging Role of ABL Kinases in Solid Tumors","volume":"1","author":"Wang","year":"2015","journal-title":"Trends Cancer"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"105384","DOI":"10.1016\/j.jff.2022.105384","article-title":"Silymarin in Cancer Therapy: Mechanisms of Action, Protective Roles in Chemotherapy-Induced Toxicity, and Nanoformulations","volume":"100","author":"Wang","year":"2023","journal-title":"J. Funct. Foods"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Deng, S., Yan, T., Jendrny, C., Nemecek, A., Vincetic, M., G\u00f6dtel-Armbrust, U., and Wojnowski, L. (2014). Dexrazoxane May Prevent Doxorubicin-Induced DNA Damage via Depleting Both Topoisomerase II Isoforms. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-842"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.tips.2022.10.003","article-title":"Mitochondrial Quality Control Mechanisms as Therapeutic Targets in Doxorubicin-Induced Cardiotoxicity","volume":"44","author":"Wu","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4287","DOI":"10.1016\/j.apsb.2022.11.007","article-title":"Small Molecule-Based Immunomodulators for Cancer Therapy","volume":"12","author":"Wu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/CAD.0000000000000513","article-title":"A Survey of Renal Impairment Pharmacokinetic Studies for New Oncology Drug Approvals in the USA from 2010 to Early 2015","volume":"28","author":"Xiao","year":"2017","journal-title":"Anticancer Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"105283","DOI":"10.1016\/j.isci.2022.105283","article-title":"Role of Non-Cardiomyocytes in Anticancer Drug-Induced Cardiotoxicity: A Systematic Review","volume":"25","author":"Xie","year":"2022","journal-title":"iScience"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.ijrobp.2021.07.035","article-title":"Assessment of Prognostic Value of High-Sensitivity Cardiac Troponin T for Early Prediction of Chemoradiation Therapy-Induced Cardiotoxicity in Patients with Non-Small Cell Lung Cancer: A Secondary Analysis of a Prospective Randomized Trial","volume":"111","author":"Xu","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"E58","DOI":"10.1016\/j.ijrobp.2017.06.728","article-title":"HEART (Heart Evaluation after Radiation Therapy): Novel Detection of Cardiotoxicity in Breast Cancer Patients","volume":"99","author":"Yang","year":"2017","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"741451","DOI":"10.3389\/fphar.2021.741451","article-title":"Cardiotoxicity of Epidermal Growth Factor Receptor 2-Targeted Drugs for Breast Cancer","volume":"12","author":"Yang","year":"2021","journal-title":"Front. Pharmacol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/10\/1441\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:04:44Z","timestamp":1760130284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/10\/1441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,11]]},"references-count":95,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["ph16101441"],"URL":"https:\/\/doi.org\/10.3390\/ph16101441","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,11]]}}}